Written by : Jayati Dubey
January 17, 2025
Source: X (Twitter)
The lab is integrated with a Laboratory Information Management System (LIMS) and intelligent systems to design CRISPR guides, streamlining the research process.
Bengaluru-based biotechnology startup CrisprBits has inaugurated a cutting-edge CRISPR gene editing and diagnostics laboratory in the city.
The facility is equipped with advanced infrastructure tailored to genomic research and molecular diagnostics, featuring specialized sections for lyophilization, cell and tissue culture, bacterial culture, and molecular biology research.
It also includes a cleanroom for sensitive operations and a dedicated gene editing section for stem cell research.
Enhancing its technological edge, the lab is integrated with a Laboratory Information Management System (LIMS) and intelligent systems to design CRISPR guides, streamlining the research process.
At the inauguration, Dr Vijay Chandru, Co-founder and Director of CrisprBits, highlighted the facility’s importance in addressing pressing health and environmental challenges.
“The launch of our new facility in Bengaluru is a significant step in our mission to provide affordable, high-quality solutions that enhance health outcomes and create commercial and social impact,” he said.
Founded in 2020 by a multidisciplinary team comprising Dr Vijay Chandru, Sunil Arora, Dr Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, CrisprBits has been dedicated to advancing CRISPR technology.
The company is supported by a women-led scientific and executive team, including experts like Vaijayanti Gupta, Reety Arora, and Vandana Hegde.
The startup, initially incubated at the Centre for Cellular and Molecular Platforms (C-CAMP), has spent four years developing a rapid point-of-need molecular diagnostics platform.
Over the coming months, CrisprBits plans to launch diagnostic tests targeting rare diseases, hospital-acquired infections (HAIs), and antimicrobial resistance.
The company continues to collaborate with C-CAMP on gene editing projects and is focusing on developing induced pluripotent stem cell (iPSC) models for rare diseases.
Additionally, CrisprBits aims to advance targeted editing of cell lines and microbes for applications in industrial microbiology, with significant developments anticipated in the next six months.
Stay tuned for more such updates on Digital Health News.